Human ELFN2/LRRC62/PPP1R29 ORF/cDNA clone-Lentivirus particle (NM_052906.5)

Cat. No.: vGMLV001508

Pre-made Human ELFN2/LRRC62/PPP1R29 Lentiviral expression plasmid for ELFN2 lentivirus packaging, ELFN2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collection

Go to ELFN2/LRRC62 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLV001508 Human ELFN2 Lentivirus particle Pilot Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
Research Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMLV001508
Gene Name ELFN2
Accession Number NM_052906.5
Gene ID 114794
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 2463 bp
Gene Alias LRRC62,PPP1R29
Fluorescent Reporter Firefly luciferase
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGCTGCGCCTGGGGCTGTGCGCGGCGGCGCTGCTGTGCGTGTGCCGGCCGGGTGCCGTGCGTGCCGACTGCTGGCTCATTGAGGGCGACAAGGGCTACGTGTGGCTGGCCATCTGCAGCCAGAACCAGCCGCCCTACGAGACCATCCCGCAGCACATCAATAGCACCGTGCACGACCTGCGGCTCAACGAGAACAAGCTCAAAGCCGTGCTCTACTCCTCGCTCAACCGCTTTGGGAACCTCACCGACCTCAACCTCACCAAGAACGAGATCTCCTACATCGAGGACGGTGCCTTCCTGGGCCAGTCGAGCCTGCAGGTCCTGCAGCTGGGCTACAACAAGCTCAGCAACCTGACGGAGGGCATGCTGCGAGGCATGAGCCGCCTGCAGTTCCTCTTTGTCCAGCACAACCTCATCGAGGTGGTGACGCCCACCGCCTTCTCCGAGTGCCCGAGCCTCATCAGCATCGACCTGTCCTCCAACCGCCTCAGCCGCCTGGACGGTGCCACCTTTGCCAGCCTCGCCAGCCTGATGGTGTGTGAGCTGGCCGGCAACCCCTTCAACTGTGAGTGCGACCTCTTCGGCTTCCTGGCCTGGCTGGTGGTCTTCAACAACGTCACCAAGAACTACGACCGCCTGCAGTGTGAGTCGCCGCGGGAGTTTGCCGGCTACCCGCTGCTGGTGCCCCGGCCCTACCACAGCCTCAACGCCATCACCGTACTCCAGGCCAAGTGTCGGAATGGCTCGCTGCCCGCCCGGCCCGTGAGCCACCCCACGCCCTACTCCACCGACGCCCAGAGGGAGCCAGACGAGAACTCGGGCTTCAACCCCGACGAGATCCTTTCGGTGGAGCCGCCGGCCTCGTCCACCACGGATGCGTCGGCAGGGCCAGCCATCAAGCTGCACCACGTCACGTTCACCTCGGCCACCCTGGTGGTCATCATCCCACACCCCTACAGCAAGATGTACATCCTCGTGCAGTACAACAACAGCTACTTCTCCGACGTCATGACCCTCAAGAACAAGAAGGAGATCGTGACGCTGGACAAACTGCGGGCGCACACTGAGTACACCTTCTGCGTGACCTCGCTGCGCAACAGCCGCCGCTTCAACCACACCTGCCTGACCTTCACCACGCGGGACCCCGTCCCCGGAGACTTGGCGCCCAGCACCTCCACCACCACCCACTACATCATGACCATCCTGGGCTGCCTCTTTGGCATGGTTATCGTGCTGGGAGCCGTGTACTACTGCCTGCGCAAGCGGCGCATGCAGGAGGAGAAGCAGAAGTCTGTCAACGTCAAGAAGACCATCCTGGAGATGCGCTACGGGGCTGATGTGGATGCCGGCTCCATTGTGCACGCCGCCCAGAAGCTGGGCGAGCCTCCCGTGCTGCCCGTATCTCGCATGGCCTCCATCCCCTCCATGATCGGGGAGAAGCTGCCCACCGCCAAGGGGTTGGAGGCCGGGCTGGACACACCCAAGGTAGCCACCAAAGGCAACTATATCGAGGTGCGCACAGGCGCCGGCGGGGACGGTCTGGCTCGGCCCGAGGATGACCTCCCGGACCTCGAGAACGGCCAGGGCTCGGCTGCAGAGATCTCCACCATTGCCAAGGAGGTGGACAAGGTCAACCAGATCATTAACAACTGCATCGATGCTCTCAAGCTGGACTCGGCCTCTTTTCTGGGAGGCGGCAGCAGCAGTGGGGACCCCGAGCTGGCCTTCGAGTGCCAGTCCCTCCCTGCAGCTGCTGCCGCCTCCTCAGCCACTGGCCCCGGGGCCCTGGAGCGGCCCAGCTTCCTTTCGCCTCCCTACAAGGAGAGCTCCCACCACCCACTACAGCGCCAGCTGAGCGCCGACGCGGCCGTGACCCGCAAGACCTGCAGCGTGTCGTCCAGTGGTTCCATCAAGAGCGCCAAGGTCTTTAGCCTGGACGTGCCCGACCATCCGGCCGCCACAGGGCTGGCTAAGGGCGACTCCAAGTACATCGAGAAGGGCAGCCCCCTCAACAGCCCGCTGGACCGGCTCCCGCTGGTGCCGGCGGGCAGCGGCGGGGGCAGCGGCGGGGGCGGGGGCATCCACCACCTGGAGGTGAAGCCGGCCTACCACTGCAGCGAGCACCGGCACAGCTTTCCCGCCCTGTACTACGAGGAGGGTGCCGACAGCCTGAGCCAGCGCGTGTCCTTCCTCAAGCCGCTGACCCGCTCCAAGCGTGACTCCACCTACTCGCAGCTCTCCCCCAGACACTACTACTCAGGGTACTCCTCCAGCCCCGAGTACTCATCCGAGAGCACGCACAAGATCTGGGAGCGCTTCCGGCCCTACAAGAAGCACCACCGGGAGGAGGTGTACATGGCCGCCGGTCACGCCCTGCGCAAGAAGGTCCAGTTCGCCAAGGACGAGGATCTGCATGACATCCTTGATTACTGGAAGGGGGTCTCCGCCCAGCAGAAGCTGTGA
ORF Protein Sequence MLRLGLCAAALLCVCRPGAVRADCWLIEGDKGYVWLAICSQNQPPYETIPQHINSTVHDLRLNENKLKAVLYSSLNRFGNLTDLNLTKNEISYIEDGAFLGQSSLQVLQLGYNKLSNLTEGMLRGMSRLQFLFVQHNLIEVVTPTAFSECPSLISIDLSSNRLSRLDGATFASLASLMVCELAGNPFNCECDLFGFLAWLVVFNNVTKNYDRLQCESPREFAGYPLLVPRPYHSLNAITVLQAKCRNGSLPARPVSHPTPYSTDAQREPDENSGFNPDEILSVEPPASSTTDASAGPAIKLHHVTFTSATLVVIIPHPYSKMYILVQYNNSYFSDVMTLKNKKEIVTLDKLRAHTEYTFCVTSLRNSRRFNHTCLTFTTRDPVPGDLAPSTSTTTHYIMTILGCLFGMVIVLGAVYYCLRKRRMQEEKQKSVNVKKTILEMRYGADVDAGSIVHAAQKLGEPPVLPVSRMASIPSMIGEKLPTAKGLEAGLDTPKVATKGNYIEVRTGAGGDGLARPEDDLPDLENGQGSAAEISTIAKEVDKVNQIINNCIDALKLDSASFLGGGSSSGDPELAFECQSLPAAAAASSATGPGALERPSFLSPPYKESSHHPLQRQLSADAAVTRKTCSVSSSGSIKSAKVFSLDVPDHPAATGLAKGDSKYIEKGSPLNSPLDRLPLVPAGSGGGSGGGGGIHHLEVKPAYHCSEHRHSFPALYYEEGADSLSQRVSFLKPLTRSKRDSTYSQLSPRHYYSGYSSSPEYSSESTHKIWERFRPYKKHHREEVYMAAGHALRKKVQFAKDEDLHDILDYWKGVSAQQKL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-SE0171-Ab Anti-PPR29/ ELFN2/ LRRC62 functional antibody
    Target Antigen GM-Tg-g-SE0171-Ag ELFN2 protein
    ORF Viral Vector pGMLV001508 Human ELFN2 Lentivirus plasmid
    ORF Viral Vector vGMLV001508 Human ELFN2 Lentivirus particle


    Target information

    Target ID GM-SE0171
    Target Name ELFN2
    Gene ID 114794, 207393, 697071, 100910536, 123378922, 481269, 528562, 100069756
    Gene Symbol and Synonyms 6330514E13,ELFN2,Elfn2-ps1,LOC123378922,LRRC62,PPP1R29,RGD1559693
    Uniprot Accession Q5R3F8
    Uniprot Entry Name PPR29_HUMAN
    Protein Sub-location Secreted Protein/Potential Cytokines
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000166897
    Target Classification Not Available

    Predicted to enable protein phosphatase inhibitor activity. Predicted to be involved in negative regulation of catalytic activity. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2022]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.